Latest News

  • CARAT at EBMT in Lisbon

    During the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) in Lisbon, Portugal, CARAT was very active in further promoting CAR T cells for cellular therapy. A central event was the very successful joint EBMT-CARAT session on March 19, 2018 chaired by Christian Chabannon (Aix-Marseille University School of...
  • Cell Therapy – Challenges & Success Stories

    CARAT approach mentioned as solution for challenges in GoingPublic Magazin
  • CAR T-Cell Immunotherapy Named Advance of the Year in Annual ASCO Report

    A new and unique new way to treat cancer – CAR T-cell therapy – is poised to transform the outlook for children and adults with certain otherwise incurable cancers. The American Society of Clinical Oncology (ASCO) named this type of adoptive cell immunotherapy the Advance of the Year in its annual report. Released within the scope of the World...
  • CARAT Training Fellowship

    GMP-compliant CAR T Cell Manufacturing Training Course December 10-14, 2018
  • Medical College of Wisconsin: first successful treatment of CART patient and use of Miltenyi’s CliniMACS Prodigy®

    The Medical College of Wisconsin has published a press release reporting on their first successfully treated CART patient and how they used Miltenyi’s CliniMACS Prodigy®.  Physicians and researchers from the Medical College of Wisconsin (MCW), Froedtert Hospital, Children's Hospital of Wisconsin, and BloodCenter of Wisconsin have...
  • First CARAT training course on “GMP-compliant CAR T cell manufacturing” completed

    Just at the end of the first half of the CARAT project, a first one-week training course on “GMP-compliant CAR T cell manufacturing” took place on December 11-15, 2017at Miltenyi Biotec headquarters in Bergisch Gladbach, Germany. Five outstanding scientists from all over Europe with profound experience in the cell and gene therapy field were...
  • New CAR T-Cell Therapy Approved by the FDA for the Treatment of Patients With Relapsed or Refractory Large B-Cell Lymphoma

    In October 2017, the pharmaceutical company Kite announced that the U.S. Food and Drug Administration (FDA) has granted regular approval to Yescarta™, the first chimeric antigen receptor T cell (CAR T) therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. This...
  • Combating Leukaemia: German TV Broadcast on CAR T-Cell Therapy

    The German regional TV station WDR broadcasted a contribution on December 12, 2017 on CAR T-cells focusing on the benefits for patients but mentioning also the high costs of the treatment and the severe side effects. One of the interview partners is Prof Klaus Cichutek, Head of Paul-Ehrlich-Institut (PEI) who is also a partner in CARAT. CAR...

Upcoming Events